Psychostimulant Treatment of TBI-Related Attention Deficits: fMRI Analysis of Neural Mechanisms of Response.
Phase of Trial: Phase III
Latest Information Update: 23 May 2017
At a glance
- Drugs Lisdexamfetamine (Primary)
- Indications Brain injuries; Chronic brain damage
- Focus Therapeutic Use
- 10 Apr 2017 Status changed from completed to discontinued.
- 03 Jun 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 26 Jun 2013 Planned end date changed from 1 Jun 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.